ABSTRACT. Several recent studies have suggested an association between proton pump inhibitors and the development of cognitive changes. Objective: To assess the existence of this association. Methods: ...

Report with market evolution powered by AI - The global proton pump inhibitors (PPIs) market size is estimated to grow by USD 819.5 million from 2025-2029, according to Technavio. The market is ...

Lee YJ, Kim J, Yu DH, Je NK, Rhee H. Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study. Sci Rep . 2024 Dec 28 ...

Growth in product launches by key players is expected to fuel the overall proton pump inhibitors (PPIs) market value during the forecast period.Wilmington, Delaware, United States, Transparency ...

ABSTRACT. BACKGROUND: Intravenous (IV) use of proton pump inhibitors (PPIs) is advised only in cases of suspected upper gastrointestinal bleeding (UGIB) or impossibility of receiving oral medication, ...

Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic hemostasis ...

[19] , which reported inferior results with IV bolus PPI therapy compared to continuous infusions in peptic ulcer bleeding patients, particularly those with high-risk features. The prevailing ...

Zhu KJ, Feng W, Ma XN, et al. Proton pump inhibitor use associated with an increased risk of gout: A population-based case-control study. Int J Rheum Dis. Published online July 20, 2023. doi:10. ...